Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024
April 10, 2024 07:00 ET
|
Crescendo Biologics
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 Preclinical data demonstrate strong rationale for...
Crescendo Biologics to present at the 2024 AACR Annual Meeting
March 06, 2024 07:00 ET
|
Crescendo Biologics
Crescendo Biologics to present at the 2024 AACR Annual Meeting Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted...
BioNTech und Crescendo Biologics geben globale Kollaboration zur Entwicklung multispezifischer Präzisionsimmuntherapien bekannt
January 10, 2022 08:00 ET
|
BioNTech SE
Die Zusammenarbeit kombiniert BioNTechs unternehmenseigene multimodulare Immuntherapie-Expertise mit Crescendos proprietärer Humabody® VH Plattform zur Entwicklung von Präzisionsimmuntherapien,...
BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies
January 10, 2022 08:00 ET
|
BioNTech SE
Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based...